skip to Main Content

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies

From left to right: Dr. Rafi Hofstein, president and CEO of MaRS Innovation; Professor Ruth Ross, director of the Centre for Collaborative Drug Research at the University of Toronto; Guy Seabrook, vice president of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, California; the Honourable Reza Moridi, Minister of Research &Innovation; and Chris Halyk, president of Janssen Inc.
From left to right: Dr. Rafi Hofstein, president and CEO of MaRS Innovation; Professor Ruth Ross, director of the Centre for Collaborative Drug Research at the University of Toronto; Guy Seabrook, vice president of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, California; the Honourable Reza Moridi, Minister of Research &Innovation; and Chris Halyk, president of Janssen Inc.

TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer’s disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million contribution to the Neuroscience Catalyst consortium, bringing the total raised for the open innovation fund to $3.7 million. Reza Moridi, Minister of Research and Innovation and Minister of Training Colleges and Universities, announced the contribution at the 2015 BIO International conference in Philadelphia during the opening of the Ontario pavilion.

This release was covered by Pharma TV and in TechVibes, BioSpace and Biotechnology Focus, and was referenced on the Canadian Science Policy Centre‘s and the Alzheimer Society of Toronto’s respective websites.

“We are pleased to support this collaborative innovation model which will accelerate the development of better treatment options for people with neurological disorders,” said Minister Moridi. “Partnerships between universities, academic hospitals, research institutes, industries and government are key to positioning Ontario as a global leader in Life Sciences.”

Founded by the University of Toronto (U of T) in partnership with Janssen Inc. and facilitated by Johnson & Johnson Innovation, the Neuroscience Catalyst consortium is using the Toronto research community’s well-established strengths in neuroscience to identify promising early-stage molecules and technologies through an open innovation model. The consortium aims to combine expertise to enable and accelerate the translation of basic sciences through to start-up companies and investor partnerships.

“We all want the next generation of solutions that are so desperately needed by patients and their families,” said Professor Ruth Ross, director of the Centre for Collaborative Drug Research at U of T. “In Canada, mood disorders such as depressive disorder and bipolar disorder affect about 10 per cent of the population. Alzheimer’s disease affects more than 745,000 Canadians. The need is urgent and this unique open collaborative partnership will allow us to rapidly develop new treatments.”

Other partners joining the project include MaRS Innovation, which introduced the partners to the Ministry of Research & Innovation and led the early conversation; Evotec, a global, high-quality provider in the drug discovery field; and Ontario Centres of Excellence (OCE), which is administering the funding.

Continue Reading

MI’s head of imaging technologies quoted on bioprinting in U.K.’s Financial Times

Fanny Sie
Fanny Sie, head of imaging technologies, is also a manager with MaRS Innovation’s Technology & Venture group.

Fanny Sie, MaRS Innovation’s head of imaging technologies, was quoted in Tanya Powley‘s article, “Printing whole organs remains a long way off,” for the U.K.’s Financial Times on June 11, 2015, regarding the technology’s potential to transform existing healthcare practices.

MI does wish to note that the article inaccurately attributes the PrintAlive device’s development to MaRS Innovation; MI is working with the University of Toronto inventing team, led by Dr. Axel Gunther, to commercialize the device.

Here’s a short excerpt:

Bioprinting could save pharmaceutical companies a lot of money, according to Fanny Sie of MaRS Innovation, a Toronto-based company. The company has developed the PrintAlive Bioprinter, which can print skin that could be used to treat people with large scale burns. The printed tissues could be used by pharmaceutical companies to test the toxicity of new drugs, and help them decide if it is worth starting costly animal and then human clinical trials.

Continue Reading

MaRS Innovation forms third collaboration with Johnson & Johnson Innovation

MaRS Innovation LogoMaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest.

The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615).

This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech.

Earlier this year, Johnson & Johnson Innovation and MaRS Innovation announced their research partnership to advance three technologies focused on improving cardiac surgery outcomes, developing a blood test for depression, and identifying a diagnostic metabolite for both gestational and type 2 diabetes patients. The projects’ principal investigators are researchers from the University Health Network (Peter Munk Cardiac Centre), the Centre for Addiction and Mental Health (with Indoc Research) and the University of Toronto.

“Johnson & Johnson Innovation is an excellent partner that understands exactly the kind of technology pipeline MaRS Innovation represents,” said Dr. Raphael Hofstein, president and CEO. “Renewing their longstanding relationship signals the value they see in this partnership with MaRS Innovation, our members and researchers within our network.”

Continue Reading

Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.

The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:

The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office in 2005, but the solitudes of thought concerning how Canada supports basic and commercial research persist.

This thinking is most easily spotted after the government announces a federal budget, triggering a flurry of opinion pieces debating the breakdown for the $2.7 billion Canada spends on research.

Most recently, Jim Balsillie, co-founder of Research in Motion (now BlackBerry Ltd.), wrote for the Globe & Mail about the Canadian need to understand that “geopolitics is at the heart of commercializing ideas,” and create better policies to protect Canadian ideas, including “better
incentives for researchers to spur commercialization,” such as during an academic’s consideration for tenure. Yet, like any business endeavor whose success depends on people, there’s more involved in changing Canada’s approach to commercialization than just policy.

The people must want to change, too.

Continue Reading

Onyx Motion’s digital coach Swish featured on Canada AM

Swish, by Onyx Motion, is a wearable virtual coach that helps basketball players improve their shooting technique while emulating their hardcourt heroes.
Swish, by Onyx Motion, is a wearable virtual coach that helps basketball players improve their shooting technique while emulating their hardcourt heroes.

UTEST company Onyx Motion‘s lead product, Swish — a basketball virtual coach that currently works with Android Wear smartwatches to help basketball athletes to improve their shooting technique and emulate their heroes — was featured on Canada AM this morning.

Watch the clip of Onyx Motion’s Swish on Canada AM, CTV’s flagship morning show. Product feature plays after advertisements and begins at 1:40 mark.

Think you’ve got an equally great software-based idea for a start-up? UTEST is currently recruiting for its fourth cohort.

Tom Emrich, a Toronto-based consultant and blogger who specializes in mobile, tablets and wearable technology, presented Swish to Canada AM hosts Marci Ien, Beverly Thomson and Jeff Hutcheson using a Sony SmartWatch 3.

“The application takes your form, measures it and, using the motion sensor of the smartwatch, compares it to experienced players’ data and provides you with a tip,” Emrich explained. “It’s really trying to make sure your next shot is going to be a slam dunk.”

Onyx Motion is part of UTEST’s third cohort. The incubator program, which MaRS Innovation co-directs with the University of Toronto. UTEST is currently recruiting companies to its fourth cohort.

Continue Reading

Globe and Mail features UTEST company eQOL’s home dialysis technology

EQOL logo“When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment,” writes Jordana Dixon in “Health startup helps patients become more independent,” for the Globe and Mail on April 13, 2015.

eQOL Inc. is a University of Toronto and MaRS Innovation start-up company that participated in and graduated from the University of Toronto Early-Stage Technology (UTEST) program’s second cohort.

UTEST is currently accepting applications for its fourth cohort.

Here’s an excerpt from the article:

Taking these complications into consideration, Mr. Nguyen envisioned an all-encompassing lateral system that would optimize the process of in-home dialysis utilizing technology, but most importantly, improving patient experience.

Continue Reading

How to get accepted into the UTEST start-up incubator: Drive and differentiation

UTEST is now accepting applications to Cohort 4

utestEditor’s note: As of today, the University of Toronto Early-Stage Technology (UTEST) program, which MaRS Innovation co-directs with the University of Toronto, is accepting applications for Cohort 4. The full application is available on the UTEST website.
 In meantime, it’s our pleasure to reprint Brianna Goldberg’s “day-in-the-life-of-an-entrepreneur” feature on Cohort 3 company Nvest, published for U of T News.

Jackie Yan focuses on tweaking his PowerPoint slide deck despite the chaos unfolding around him.

Nvest team at work in front of a computer

Near the entrance to the office space he shares with teams from the six other startups that are part of the UTEST accelerator program, a phone spits distorted tones of an investment-related conference call at Hanna Tomory, CEO of a fatigue-management start-up called Syncadian, as she scratches a list of notes.

A few steps down the hall, Marissa Wu, founder of the digital sports coaching wearable startup called Onyx Motion, goes over presentation notes with her co-founder Vivek Kesarwani. They discuss the finer points of athlete training with the intensity of so many layup drills performed on the basketball net propped against the wall of their desk space.

Across the table in the conference room where Yan is feverishly editing his slides, James McCrae pieces together 3D sculptures of horses, wasps and dinosaurs created with software from his start-up, FlatFab.

“We’re hoping to make more stable structures with our 1.0 design, maybe integrating finger-joints,” McCrae explains as he prepares to demo FlatFab’s wares for a video crew from the Privy Council Office in Ottawa, Ontario.

The videographers are producing a video about MaRS Innovation today, which co-directs the UTEST accelerator program with the University of Toronto, and are capturing b-roll of UTEST founders at work on their ventures. With seven companies currently sharing the working space, there’s always something happening.

Continue Reading

UTEST company Nvest is bringing accountability to investment recommendations

Nvest LogoNvest, a University of Toronto company, is gaining traction as a financial technology (or fintech) start-up to watch. Nvest is part of the third UTEST cohort, which is an early-stage technology incubator program co-directed by MaRS Innovation and U of T (read more about the UTEST program in our portfolio section).

utestIn the last month, Nvest has been profiled in both TechVibes and Investment Executive as a company to watch both as a social network for stock picking and as a tool to bringing accountability to investment recommendations.

Jacob Serebrin writes for TechVibes:

Fredrick Zhou says there’s something wrong with the way people recommend stocks online.

“People don’t take responsibility for their actions, their words and their recommendations,” Zhou says.

He’s the co-founder and CEO of Nvest, a new social network for stock pickers that he says will bring accountability and transparency to a broken system.

Continue Reading

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries

ChipCare device
ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing for remote health settings. The University of Toronto start-up company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016.

TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products.

The Wall Street Journal‘s Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub covered this announcement, along with the University of Toronto’s news site and a follow-up BetaKit article on how smartphones and start-ups are increasing access to healthcare. Information about past ChipCare  investment rounds and other company information is available in our ChipCare news archive.

Insufficient access in remote health settings to simple, accurate and affordable diagnostic tests makes it difficult to provide timely, evidence-based clinical care. Current technology within central laboratories cannot fulfill the existing need in remote health settings, including community level health facilities, remote communities, emergency departments, ICUs and doctors’ offices. The result is millions of preventable deaths from infectious and non-communicable diseases globally, reduced economic growth, and limited human development.

Chipcare CorporationChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing in remote health settings. The company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016. The company is developing other products that leverage unique attributes of ChipCare’s technology.

Puffin Partners, LP, of Dallas, Texas led the financing round, which includes existing investors MaRS Innovation and Maple Leaf Angels, and new investors, including the Winfield Venture Group, Epic Capital, and additional Canadian and U.S. Angel investors.

Continue Reading

Portfolio round-up: UTEST, Nvest and Whirlscape news

utestSometimes there’s so much happening with the MaRS Innovation portfolio that it’s hard to stay on top of all the news. Here are a few UTEST program stories that we missed in February.

  • UTEST was named to FundThrough.com’s list of “6 Exciting Canadian Startup Accelerators to Watch in 2015.” Program co-directors Mike Betts and Kurtis Scissons point out that UTEST does take an equity position in the incubated companies and does not run on a grant basis as mentioned in the article. (It’s a sweetheart deal, but not that sweet.)
  • Nvest LogoUTEST company Nvest was featured in a Globe and Mail story, “Next big sector to face disruption? Financial services” by Brenda Bouw. Here’s a quote:
    “Another emerging fintech startup is Nvest, an early-stage, crowd-sourced stock recommendation platform. Nvest compiles recommendations from its users, many of which are average retail investors, and builds a performance history others can track. The credibility of recommendations is based on a user’s past performance. Nvest co-founder Fredrick Zhou likens it to LinkedIn for stock recommendations. ‘Nvest is a place where investors post their trading resume.’ Investors are taking notice. Nvest recently received funding from the University of Toronto Early Stage Technology program and it is in the process of pitching the business to angel investors.”
Continue Reading
Back To Top